Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Echinacea/cold study

This article was originally published in The Tan Sheet

Executive Summary

Liquid Echinacea purpurea extract "did not significantly decrease the incidence, duration or severity of colds and respiratory infections compared to placebo," Wolfram Grimm, MD, and Hans-Helge Muller, PhD, University of Marburg, Germany, report in the February American Journal of Medicine. A total of 108 subjects with a history of frequent infections took either 4 ml of echinacea or "placebo-juice" twice a day and were followed for eight weeks. Of the 54 subjects receiving echinacea, 35 (65%) had at least one respiratory infection, compared to 40 (74%) in the placebo group. Median length of illness was 4.5 days in the echinacea group and 6.5 days for those on placebo. In a separate editorial, Stephen Bent, MD, and Andrew Avins, MD, University of California San Francisco, write that echinacea accounts for 12% of all U.S. herbal sales, and thereby justifies rigorous clinical study. However, due to herbal companies' low research budgets, "we will continue to see provocative, but ultimately unsatisfying, studies of herbal products," Bent and Avins say

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS089466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel